

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE
COVERAGE INFORMATION AND SPECIAL CONSIDERATIONS**

Florida Medicaid providers administering vaccines to Florida Medicaid recipients, must submit two Current Procedural Terminology (CPT) codes: a vaccine product code as well as the vaccine administration code on the claim for reimbursement of administration from Florida Medicaid for recipients enrolled in the fee-for-service delivery system. A corresponding administration code must be submitted for each vaccine administered during the same visit on the claim form.

Florida Medicaid providers receiving vaccine products through the Vaccine for Children (VFC) Program for fee-for-service recipients 0 through 18 years of age are reimbursed for the administration of the vaccine(s) only. The vaccine product codes are reimbursed at \$0.00, vaccine administration codes are reimbursed in accordance with rates established on this fee schedule.

MediKids enrolls children one through four years of age and are eligible for all immunizations recommended by the Advisory Committee on Immunization Practices (ACIP) for this age group. Florida Medicaid providers who administer vaccines to MediKids enrollees are to be reimbursed for the vaccine products and administration services by the Managed Care Plan. MediKids enrollees are not eligible to receive products provided through the VFC Program.

Administration services are reimbursed at 80% of the maximum fee when performed by an advanced practice registered nurse (APRN), physician's assistant (PA), or registered pharmacist (RPh).

Florida Medicaid providers administering COVID-19 vaccines to Florida Medicaid recipients must submit both the appropriate CPT code for the specific vaccine product in conjunction with the product specific vaccine administration code on the claim for reimbursement of administration from Florida Medicaid for recipients enrolled in the fee-for-service delivery system. The manufacturer-specific products and their dose-specific administration code must be submitted for each vaccine dose administered on the claim form.

**COVID-19 Vaccine & Administration Codes as of September 12, 2023.*

Italicized print, not authorized for use in the United States as of September 11, 2023.

^Respiratory Syncytial Virus monoclonal antibody codes have specific administration codes that must be billed together.

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

Code	Modifier	Description	Units	Age (Years)	MaxFee
90688		Influenza vaccine intramuscular administration, 0.5ml dosage, quadrivalent MDV	1	0 - 18	0.00
90688	HA	Influenza vaccine intramuscular administration, 0.5ml dosage, quadrivalent MDV	1	19+	18.44
90685		Influenza vaccine, intramuscular administration, 0.25ml dosage, quadrivalent, preservation free	1	0-3	0.00
90686		Influenza vaccine, intramuscular administration, 0.5ml dosage, quadrivalent, preservation free	1	0 - 18	0.00
90686	HA	Influenza vaccine, intramuscular administration, 0.5ml dosage, quadrivalent, preservation free	1	19+	19.73
90657		Influenza vaccine for administration into muscle, 0.25ml dosage	1	0-2	0.00
90658		Influenza vaccine for administration into muscle, 0.5ml dosage	1	0 - 18	0.00
90658	HA	Influenza vaccine for administration into muscle, 0.5ml dosage	1	19+	19.22
90620		Meningococcus recombinant protein for injection into muscle, 2 dose schedule (MenB-4C)	1	10-18	0.00
90620	HA	Meningococcus recombinant protein for injection into muscle, 2 dose schedule (MenB-4C)	1	19+	211.32
90715		Tetanus, diphtheria toxoids, and acellular pertussis (whooping cough) (TDaP), intramuscular	1	7 - 18	0.00

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

Code	Modifier	Description	Units	Age (Years)	MaxFee
90715	HA	Tetanus, diphtheria toxoids, and acellular pertussis (whooping cough) (TDaP), intramuscular	1	19+	52.41
90700		Diphtheria, tetanus, and acellular pertussis (whooping cough) (DTaP), intramuscular	1	0-6	0.00
90702		Diphtheria and tetanus toxoids, intramuscular	1	0-7	0.00
90682		Influenza vaccine derived from DNA (RIV4) for injection into muscle, quadrivalent, preservative and antibiotic free (Flublok)	1	18	0.00
90682	HA	Influenza vaccine derived from DNA (RIV4) for injection into muscle, quadrivalent, preservative and antibiotic free (Flublok)	1	19+	63.76
90756		Influenza vaccine derived from cell cultures, intramuscular, quadrivalent, antibiotic free, 0.5ml	1	0-18	0.00
90674		Influenza vaccine derived from cell cultures (ccIV4) preservative/antibiotic free 0.5ml intramuscular	1	0-18	0.00
90674	HA	Influenza vaccine derived from cell cultures (ccIV4) preservative/antibiotic free 0.5ml intramuscular	1	19+	30.10
90756	HA	Influenza vaccine derived from cell cultures, intramuscular, quadrivalent, antibiotic free, 0.5ml	1	19+	28.52
90687		Influenza vaccine intramuscular administration, 0.25ml dosage, quadrivalent	1	0-3	0.00
90672		Influenza vaccine quadrivalent, nasal administration	1	2-18	0.00
90672	HA	Influenza vaccine quadrivalent, nasal administration	1	19+	23.75
90655		Influenza vaccine for administration into muscle, 0.25ml dosage, preservative free	1	0-2	0.00
90656		Influenza vaccine for administration into muscle, 0.5ml dosage, preservative free	1	0 - 18	0.00
90656	HA	Influenza vaccine for administration into muscle, 0.5ml dosage, preservative free	1	19+	19.76
90651		Human papilloma virus nonvalent (3 dose schedule) injection into muscle	1	9 - 18	0.00
90651	HA	Human papilloma virus nonvalent (3 dose schedule) injection into muscle	1	19-45	268.77
90739		Hepatitis B adult dosage (2 dose schedule) injection into muscle	1	18	0.00
90739	HA	Hepatitis B adult dosage (2 dose schedule) injection into muscle	1	19+	140.60
90648		Haemophilus influenzae B (4 dose schedule) injection into muscle	1	0-5	0.00
90375		Rabies immune globulin for injection beneath skin and/or into muscle	9		284.68
90376		Rabies immune globulin for injection beneath skin and/or into muscle, heat treated	9		250.09
90675		Rabies vaccine, intramuscular	1		329.99
90713		Polio vaccine, injection beneath the skin or into muscle	1	0-18	0.00
90734		Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or (MenACWY-CRM) for injection into muscle	1	0-18	0.00

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

Code	Modifier	Description	Units	Age (Years)	MaxFee
90734	HA	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or (MenACWY-CRM) for injection into muscle	1	19+	148.49
90644		Meningococcal and Haemophilus influenzae B (4 dose schedule) injection into muscle, children 6 weeks-18 months of age (Hib-MenCY)	1	0-2	0.00
90619		Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT) for injection into muscle	1	2-18	0.00
90619	HA	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT) for injection into muscle	1	19+	156.11
90707		Measles, mumps, and rubella (German measles) injection beneath skin	1	0-18	0.00
90707	HA	Measles, mumps, and rubella (German measles) injection beneath skin	1	19+	89.87
90723		Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Hepatitis B, and polio (DTaP-HepB-IPV), intramuscular	1	0-6	0.00
90647		Haemophilus influenzae B (3 dose schedule) injection into muscle	1	0-5	0.00
90698		Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Haemophilus influenza type B and polio (DTaP-HIB-IPV), intramuscular	1	0-4	0.00
90732		Pneumococcal polysaccharide 23 valent subcutaneous or intramuscular	1	2 - 18	0.00
90732	HA	Pneumococcal polysaccharide 23 valent subcutaneous or intramuscular	1	19+	117.08
90670		Pneumococcal conjugate 13 valent, intramuscular	1	0-18	0.00
90671		Pneumococcal Conjugate Vaccine 15 valent, intramuscular (PCV15)	1	0-18	0.00
90671	HA	Pneumococcal Conjugate Vaccine 15 valent, intramuscular (PCV15)	1	19+	215.37
90677		Pneumococcal Conjugate Vaccine 20 valent, intramuscular (PCV20)	1	0-18	0.00
90677	HA	Pneumococcal Conjugate Vaccine 20 valent, intramuscular (PCV20)	1	19+	253.21
90710		Measles, mumps, rubella (German measles), and varicella (chicken pox) injection beneath skin	1	1 - 12	0.00
90696		Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), and polio (DTaP-IPV), intramuscular	1	4 - 6	0.00
90743		Hepatitis B 2 (dose schedule) intramuscular	1	11 - 15	0.00
90744		Hepatitis B (3 dose schedule) intramuscular	1	0-18	0.00
90746		Hepatitis B (3 dose schedule) intramuscular	1	19+	64.90
90681		Rotavirus pentavalent (2 dose schedule) oral	1	0-1	0.00
90680		Rotavirus pentavalent (3 dose schedule) oral	1	0-1	0.00
90714		Tetanus and diphtheria toxoids, intramuscular	1	7 - 18	0.00
90714	HA	Tetanus and diphtheria toxoids, intramuscular	1	19+	39.74

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

Code	Modifier	Description	Units	Age (Years)	MaxFee
90621		Meningococcus lipoprotein for injection into muscle, 2 or 3 dose schedule (MenB-FHbp)	1	10-18	0.00
90621	HA	Meningococcus lipoprotein for injection into muscle, 2 or 3 dose schedule (MenB-FHbp)	1	19+	178.95
90632		Hepatitis A injection into muscle, adult dosage	1	18	0.00
90632	HA	Hepatitis A injection into muscle, adult dosage	1	19+	76.69
90633		Hepatitis A (2 dose schedule) injection into muscle, pediatric or adolescent dosage	1	0-18	0.00
90634		Hepatitis A (3 dose schedule) injection into muscle, pediatric or adolescent dosage	1	0-18	0.00
90716		Varicella virus (chicken pox) subcutaneous	1	0-18	0.00
90716	HA	Varicella virus (chicken pox) subcutaneous	1	19+	160.36
90697		Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), polio, Haemophilus influenza type b and hepatitis B (DTaP-IPV-HIB-HEPB), intramuscular	1	0-4	0.00
90678		Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use (ABRYSVO)	1	10-18 (PREGNANCY ONLY)	295.00
90678	HA	Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use (ABRYSVO)	1	19-59 (PREGNANCY ONLY)	295.00
90678	HA	Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use (ABRYSVO)	1	60+	295.00
90679		Respiratory Syncytial Virus vaccine, for IM use (AREXVY)	1	60+	280.00
90380		<i>Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 0.5ml dosage for IM use (BEYFORTUS)^</i>	1	0-1	0.00
90381		<i>Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 1ml dosage for IM use (BEYFORTUS)^</i>	1	0-1	0.00
90381		<i>Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 1ml dosage for IM use (BEYFORTUS)^</i>	2	1-2	0.00
96380		<i>Administration of Respiratory Syncytial Virus monoclonal antibody, seasonal dose, intramuscular, with counseling^</i>	1	0-2	10.00
96381		<i>Administration of Respiratory Syncytial Virus monoclonal antibody, seasonal dose, intramuscular^</i>	1	0-2	10.00
90750		Zoster Vaccine (HZC) recombinant, intramuscular	1	18+	183.41

ADMINISTRATION CODES

90460		Administration of first vaccine or toxoid component through 18 years of age, with counseling		0-18	10.00
90471		Administration of one vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular)			10.00
90472		Administration of each additional vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular)			10.00
90473		Immunization administration by intranasal or oral route of one vaccine, single or combination vaccine/toxoid.			10.00
90474		Administration of each additional intranasal or oral vaccine (single or combination vaccine/toxoid)			10.00

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

Code	Modifier	Description	Units	Age (Years)	MaxFee
COVID-19 VACCINE & ADMINISTRATION CODES					
90480		Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose (all manufacturers)*	1	ANY	40.00
91318		Severe acute respiratory coronavirus 2 (SARS-CoV-2-) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (Pfizer)*	1	6MO-4YRS	0.00
91319		Severe acute respiratory coronavirus 2 (SARS-CoV-2-) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (Pfizer)*	1	5-11YRS	0.00
91320		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Pfizer)*	1	12-18	0.00
91320	HA	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Pfizer)*	1	19+	115.00
91321		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.25 mL dosage, for intramuscular use (Moderna)*	1	6MO-11YRS	0.00
91322		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.5 mL dosage, for intramuscular use (Moderna)*	1	12-18	0.00
91322	HA	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.5 mL dosage, for intramuscular use (Moderna)*	1	19+	128.00
91304		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 0.5mL dosage, for intramuscular use (Novavax)	1	12+	0.00
91312	PFIZER	SARSCOV2 VAC BVL 30MCG/0.3ML (GRAY CAP)	1	12+	0.00
0121A	PFIZER	ADM SARSCV2 BVL 30MCG/.3ML SINGLE DOSE (GRAY CAP)	1	12+	0.00
0124A	PFIZER	ADM SARSCV2 BVL 30MCG/.3ML BOOSTER (GRAY CAP)	1	12+	40.00
91315	PFIZER	SARSCOV2 VAC BVL 10MCG/0.2ML (ORANGE CAP)	1	5-11	0.00
0151A	PFIZER	ADM SARSCOV2 BVL 10MCG/0.2ML SINGLE DOSE (ORANGE CAP)	1	5-11	40.00
0154A	PFIZER	ADM SARSCOV2 BVL 10MCG/0.2ML (ORANGE CAP)	1	5-11	40.00
91317	PFIZER	SARSCOV2 VAC BVL 3MCG/0.2ML (MAROON CAP)	1	6MO- 4YRS	0.00
0171A	PFIZER	ADM SARSCV2 BVL 3MCG/0.2ML FIRST DOSE (MAROON CAP)	1	6MO- 4YRS	40.00
0172A	PFIZER	ADM SARSCV2 BVL 3MCG/0.2ML 2ND DOSE (MAROON CAP)	1	6MO- 4YRS	40.00
0173A	PFIZER	ADM SARSCV2 BVL 3MCG/0.2ML 3RD DOSE (MAROON CAP)	1	6MO- 4YRS	40.00

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

Code	Modifier	Description	Units	Age (Years)	MaxFee
0174A	PFIZER	ADM SARSCV2 BVL 3MCG/0.2ML ADDITIONAL DOSE (MAROON CAP)	1	6MO- 4YRS	40.00
91313	MODERNA	SARSCOV2 VAC BVL 50MCG/0.5ML (DARK BLUE CAP GRAY BORDER)	1	12+	0.00
0134A	MODERNA	ADM SARSCV2 BVL 50MCG/.5ML BOOSTER (DARK BLUE CAP GRAY BORDER)	1	12+	40.00
91314	MODERNA	SARSCOV2 VAC BVL 25MCG/0.25ML (DARK BLUE CAP GRAY BORDER)	1	6MO-11YRS	0.00
0141A	MODERNA	ADM SARSCV2 BVL 25MCG/0.25ML FIRST DOSE (DARK BLUE CAP GRAY BORDER)	1	6MO-11YRS	40.00
0142A	MODERNA	ADM SARSCV2 BVL 25MCG/0.25ML 2ND DOSE (DARK BLUE CAP GRAY BORDER)	1	6MO-11YRS	40.00
0144A	MODERNA	ADM SARSCV2 BVL 25MCG/0.25ML ADDITIONAL DOSE (DARK BLUE CAP GRAY BORDER)	1	6MO-11YRS	40.00
91316	MODERNA	SARSCOV2 VAC BVL 10MCG/0.2ML (DARK PINK CAP)	1	6MO- 4YRS	0.00
0164A	MODERNA	ADM SRSVC2 BLV 10MCG/0.2ML ADDITIONAL DOSE (DARK PINK CAP)	1	6MO- 4YRS	40.00
0041A	NOVAVAX	ADM NOVAVAX COVID-19 VACCINE, ADJUVANTED DOSE 1	1	12+	40.00
0042A	NOVAVAX	ADM NOVAVAX COVID-19 VACCINE, ADJUVANTED DOSE 2	1	12+	40.00
0044A	NOVAVAX	ADM NOVAVAX COVID-19 VACCINE, ADJUVANTED ADDITIONAL DOSE	1	18+	40.00